Real-world effectiveness of long acting aripiprazole: Treatment persistence and its correlates in the Italian clinical practice.

•Treatment persistence refers to the act of continuing a medication over time and may be an indirect measure of efficacy and tolerability.•A relatively high number (n = 225, 86%) were persistent to A-LAI for at least 6 months.•A statistically significant difference between persistent and non-persistent subjects was observed for baseline education, occupation, CGI-S, LDPS disorganization score, psychotic spectrum paranoid and schizoid score. All subjects with baseline CGI-S of 1 or 2, 95% of subjects with CGI-S of 3, 86% with CGI-S of 4, 82% of subjects with CGI-S of 5, 73% of subjects with CGI of 6 and 90% of subjects with CGI of 7 were persistent.•A-LAI treatment continuation rate was higher in patients with: 1) baseline CGI score ≤ 4; 2) schizophrenia dimension (LDPS) mania score ≤ 5; 3) psychotic spectrum schizoid score ≤ 11.